Sentry Investment Management LLC Has $1.44 Million Stake in Iqvia Holdings Inc (IQV)

Sentry Investment Management LLC lifted its position in Iqvia Holdings Inc (NYSE:IQV) by 16.1% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 11,077 shares of the medical research company’s stock after acquiring an additional 1,540 shares during the period. Sentry Investment Management LLC’s holdings in Iqvia were worth $1,437,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Achmea Investment Management B.V. raised its holdings in shares of Iqvia by 26.2% during the third quarter. Achmea Investment Management B.V. now owns 10,867 shares of the medical research company’s stock valued at $1,409,000 after purchasing an additional 2,257 shares during the last quarter. O Shaughnessy Asset Management LLC raised its holdings in shares of Iqvia by 52.2% during the third quarter. O Shaughnessy Asset Management LLC now owns 4,863 shares of the medical research company’s stock valued at $631,000 after purchasing an additional 1,668 shares during the last quarter. Skandinaviska Enskilda Banken AB publ purchased a new position in shares of Iqvia during the third quarter valued at approximately $3,507,000. Dupont Capital Management Corp raised its holdings in shares of Iqvia by 16.7% during the third quarter. Dupont Capital Management Corp now owns 48,127 shares of the medical research company’s stock valued at $6,244,000 after purchasing an additional 6,891 shares during the last quarter. Finally, Essex Financial Services Inc. purchased a new position in shares of Iqvia during the third quarter valued at approximately $249,000. Hedge funds and other institutional investors own 91.36% of the company’s stock.

Several research firms have recently weighed in on IQV. Barclays reissued an “overweight” rating and set a $130.00 price objective (up from $120.00) on shares of Iqvia in a report on Wednesday, July 25th. Stifel Nicolaus boosted their price objective on shares of Iqvia from $128.00 to $150.00 and gave the company a “buy” rating in a report on Wednesday, July 25th. Piper Jaffray Companies boosted their price objective on shares of Iqvia to $131.00 and gave the company a “neutral” rating in a report on Tuesday, October 23rd. Wells Fargo & Co boosted their price objective on shares of Iqvia from $120.00 to $140.00 and gave the company an “outperform” rating in a report on Monday, August 13th. Finally, Mizuho set a $120.00 price objective on shares of Iqvia and gave the company a “hold” rating in a report on Monday, August 6th. Five investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. Iqvia has a consensus rating of “Buy” and an average price target of $131.67.

In other Iqvia news, Director John G. Danhakl sold 221,900 shares of the company’s stock in a transaction that occurred on Friday, September 7th. The shares were sold at an average price of $126.63, for a total value of $28,099,197.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kevin C. Knightly sold 9,216 shares of the company’s stock in a transaction that occurred on Friday, September 7th. The stock was sold at an average price of $126.46, for a total transaction of $1,165,455.36. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 601,586 shares of company stock valued at $75,510,422. 6.00% of the stock is owned by corporate insiders.

Shares of IQV stock opened at $124.17 on Friday. Iqvia Holdings Inc has a 12 month low of $91.57 and a 12 month high of $135.48. The company has a market cap of $25.62 billion, a price-to-earnings ratio of 24.97, a price-to-earnings-growth ratio of 1.82 and a beta of 0.81. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.09 and a quick ratio of 1.09.

Iqvia (NYSE:IQV) last announced its earnings results on Monday, October 22nd. The medical research company reported $1.42 EPS for the quarter, beating the Zacks’ consensus estimate of $1.39 by $0.03. Iqvia had a net margin of 12.29% and a return on equity of 13.69%. The business had revenue of $2.59 billion during the quarter, compared to analysts’ expectations of $2.58 billion. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. As a group, research analysts predict that Iqvia Holdings Inc will post 5.13 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by WKRB News and is owned by of WKRB News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.wkrb13.com/2018/11/10/sentry-investment-management-llc-has-1-44-million-stake-in-iqvia-holdings-inc-iqv.html.

Iqvia Company Profile

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Featured Story: Price to Earnings Ratio (PE)

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply